Literature DB >> 22860163

"Clicked" sugar-curcumin conjugate: modulator of amyloid-β and tau peptide aggregation at ultralow concentrations.

Sukanta Dolai1, Wei Shi, Christopher Corbo, Chong Sun, Saadyah Averick, Dinali Obeysekera, Mina Farid, Alejandra Alonso, Probal Banerjee, Krishnaswami Raja.   

Abstract

The synthesis of a water/plasma soluble, noncytotoxic, "clicked" sugar-derivative of curcumin with amplified bioefficacy in modulating amyloid-β and tau peptide aggregation is presented. Curcumin inhibits amyloid-β and tau peptide aggregation at micromolar concentrations; the sugar-curcumin conjugate inhibits Aβ and tau peptide aggregation at concentrations as low as 8 nM and 0.1 nM, respectively. In comparison to curcumin, this conveniently synthesized Alzheimer's drug candidate is a more powerful antioxidant.

Entities:  

Keywords:  Alzheimer’s disease (AD); amyloid-β; antioxidant potential; curcumin; tau peptide; “click” reaction

Mesh:

Substances:

Year:  2011        PMID: 22860163      PMCID: PMC3369720          DOI: 10.1021/cn200088r

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  38 in total

1.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

2.  A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro.

Authors:  Yasuhiro Nakagami; Satoko Nishimura; Takako Murasugi; Isao Kaneko; Masaki Meguro; Shinji Marumoto; Hiroshi Kogen; Kazuo Koyama; Tomiichiro Oda
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 3.  The blood-brain barrier and brain drug delivery.

Authors:  J M Koziara; P R Lockman; D D Allen; R J Mumper
Journal:  J Nanosci Nanotechnol       Date:  2006 Sep-Oct

4.  Inhibition of beta-amyloid fibrillization by directed evolution of a beta-sheet presenting miniature protein.

Authors:  Thaddeus J Smith; Cliff I Stains; Scott C Meyer; Indraneel Ghosh
Journal:  J Am Chem Soc       Date:  2006-11-15       Impact factor: 15.419

Review 5.  "Spicing up" of the immune system by curcumin.

Authors:  Ganesh Chandra Jagetia; Bharat B Aggarwal
Journal:  J Clin Immunol       Date:  2007-01-09       Impact factor: 8.317

6.  CHIP-ping away at tau.

Authors:  Dmitry Goryunov; Ronald K H Liem
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

7.  "Clicked" bivalent ligands containing curcumin and cholesterol as multifunctional abeta oligomerization inhibitors: design, synthesis, and biological characterization.

Authors:  James A Lenhart; Xiao Ling; Ronak Gandhi; Tai L Guo; Phillip M Gerk; Darlene H Brunzell; Shijun Zhang
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

Review 8.  Copper in the brain and Alzheimer's disease.

Authors:  Ya Hui Hung; Ashley I Bush; Robert Alan Cherny
Journal:  J Biol Inorg Chem       Date:  2009-10-28       Impact factor: 3.358

9.  The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds.

Authors:  Sean A Hudson; Heath Ecroyd; Tak W Kee; John A Carver
Journal:  FEBS J       Date:  2009-09-15       Impact factor: 5.542

10.  Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease?

Authors:  Rajeshwar Narlawar; Marcus Pickhardt; Stefanie Leuchtenberger; Karlheinz Baumann; Sabine Krause; Thomas Dyrks; Sascha Weggen; Eckhard Mandelkow; Boris Schmidt
Journal:  ChemMedChem       Date:  2008-01       Impact factor: 3.466

View more
  19 in total

Review 1.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

2.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

Review 3.  Tau-induced neurodegeneration: mechanisms and targets.

Authors:  Cindy Beharry; Leah S Cohen; Jing Di; Kawsar Ibrahim; Susan Briffa-Mirabella; Alejandra del C Alonso
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

Review 4.  Structure and mechanism of action of tau aggregation inhibitors.

Authors:  Katryna Cisek; Grace L Cooper; Carol J Huseby; Jeff Kuret
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

5.  Assessment of Novel Curcumin Derivatives as Potent Inhibitors of Inflammation and Amyloid-β Aggregation in Alzheimer's Disease.

Authors:  Johant Lakey-Beitia; Yisett González; Deborah Doens; David E Stephens; Ricardo Santamaría; Enrique Murillo; Marcelino Gutiérrez; Patricia L Fernández; K S Rao; Oleg V Larionov; Armando A Durant-Archibold
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 6.  Curcumin in Health and Diseases: Alzheimer's Disease and Curcumin Analogues, Derivatives, and Hybrids.

Authors:  Eirini Chainoglou; Dimitra Hadjipavlou-Litina
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

Review 7.  Polyphenols as therapeutic molecules in Alzheimer's disease through modulating amyloid pathways.

Authors:  Johant Lakey-Beitia; Ruben Berrocal; K S Rao; Armando A Durant
Journal:  Mol Neurobiol       Date:  2014-05-15       Impact factor: 5.590

8.  Inhibitory effect of corcin on aggregation of 1N/4R human tau protein in vitro.

Authors:  Ali Mohammadi Karakani; Gholamhossein Riazi; Seyed Mahmood Ghaffari; Shahin Ahmadian; Farzad Mokhtari; Mahshad Jalili Firuzi; Seyedeh Zahra Bathaie
Journal:  Iran J Basic Med Sci       Date:  2015-05       Impact factor: 2.699

9.  Curcuminoid submicron particle ameliorates cognitive deficits and decreases amyloid pathology in Alzheimer's disease mouse model.

Authors:  Yi-Heng Tai; Yu-Yi Lin; Kai-Chen Wang; Chao-Lin Chang; Ru-Yin Chen; Chia-Chu Wu; Irene H Cheng
Journal:  Oncotarget       Date:  2018-01-31

Review 10.  Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.

Authors:  Francesco Panza; Vincenzo Solfrizzi; Davide Seripa; Bruno P Imbimbo; Madia Lozupone; Andrea Santamato; Chiara Zecca; Maria Rosaria Barulli; Antonello Bellomo; Alberto Pilotto; Antonio Daniele; Antonio Greco; Giancarlo Logroscino
Journal:  Biomed Res Int       Date:  2016-06-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.